GTX-102Summary: A phase 1/2 open-label, multiple-dose, dose-escalating clinical trial of the safety and tolerability of GTX-102 in pediatric patients with Angelman Syndrome (AS)
GTX-102
read more
sEARCH RESULTS
ST-920-201
ST-920-201Dose-ranging study of ST-290, an AAV2/6 Human Alpha Galactosidase - a gene therapy in subjects with Fabry disease DOSE-RANGING STUDY OF ST-920, AN AAV2/6 HUMAN ALPHA GALACTOSIDASE A GENE THERAPY IN SUBJECTS WITH FABRY DISEASE